[CAS NO. 232931-57-6] SJG-136
PRODUCTS SPECIFICATIONS [232931-57-6]
DESCRIPTION [232931-57-6]
Overview
| MDL | MFCD19443671 |
|---|---|
| Molecular Weight | 556.61 |
| Molecular Formula | C31H32N4O6 |
| SMILES | O=C1N2[C@@H](CC(C2)=C)C=NC3=CC(OCCCOC4=C(OC)C=C(C(N(CC(C5)=C)[C@@H]5C=N6)=O)C6=C4)=C(OC)C=C31 |
Summary
SJG-136 is a DNA cross-linking agent, with an XL 50 of 45 nM for pBR322 DNA. SJG-136 has potent antitumor activity.
IC50 & Target
|
Pyrrolobenzodiazepines |
In Vitro
SJG-136 (dimer 5) is a DNA cross-linking agent, with an XL 50 (concentration of agent required for 50% cross-linking of pBR322 DNA) of 45 nM for pBR322 DNA. SJG-136 is cytotoxic to ovarian cell lines, such as A2780 (IC 50 , 22.5 pM), A2780cisR (IC 50 , 24 pM), CH1 (IC 50 , 0.12 nM), CH1cisR (IC 50 , 0.6 nM), and SKOV-3 (IC 50 , 9.1 nM) [1] . SJG-136 (SG2000) also reduces the viability of a panel of canine cancer cells, with GI 50 values ranging from 0.33 - >100 nM after a 1 h exposure, and <0.03 - 17.33 nM following continuous exposure [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SJG-136 shows more potent antitumor effect against CMeC-1 tumour at 0.30 mg/kg than 0.15 mg/kg either as a single dose or administered once a week for three weeks via dosed intravenously in mice. SJG-136-induced H2AX phosphorylation shows good correspondence, but less sensitivity, than measurement of foci [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00121290 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
February 2005 | Phase 1 |
| NCT00103220 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
November 2004 | Phase 1 |
| NCT00301769 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes
|
December 2005 | Phase 1 |
| NCT01200797 | National Cancer Institute (NCI) |
Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer
|
July 2010 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 33.33 mg/mL ( 59.88 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7966 mL | 8.9830 mL | 17.9659 mL |
| 5 mM | 0.3593 mL | 1.7966 mL | 3.5932 mL |
| 10 mM | 0.1797 mL | 0.8983 mL | 1.7966 mL |
References
- [1] Gregson SJ, et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem. 2001 Mar 1;44(5):737-48.
- [2] Mellinas-Gomez M, et al. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Vet Res. 2015 Aug 19;11:215.
Synonyms
